2026 FDA TRT Label Update: What the Prostate Cancer Change Means
What Changed for Tetsosterone? On June 18, 2026, HHS announced that the FDA was requesting important revisions to testosterone replacement therapy (TRT) prescribing information. Among them was a proposal to narrow the prostate-cancer contraindication from known or suspected prostate cancer to metastatic prostate cancer. The FDA also requested removal of the limitation stating that TRT’s safety and effectiveness in age-related hypogonadism had not been established, along with revisions to warnings about benign prostatic hyperplasia (BPH), or an enlarged prostate. These requests reflect an updated assessment of the evidence; they do not confirm that every testosterone product’s label has changed. Why This Matters to Patients For men whose concerns about prostate health have kept them from discussing TRT, the announcement provides a reason to revisit the conversation with a qualified physician. It does not establish that treatment is risk-free or appropriate for everyone. Symptoms, confi...